Patents Assigned to KaloBios Pharmaceuticals, Inc.
  • Antibodies to the PcrV Antigen of Pseudomonas aeruginosa
    Publication number: 20120020986
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: October 11, 2011
    Publication date: January 26, 2012
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • METHODS OF TREATING BONE-LOSS DISORDERS USING A GM-CSF ANTAGONIST
    Publication number: 20120009191
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of bone loss disorders, such as osteopenia. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has a bone loss disorder and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: July 8, 2011
    Publication date: January 12, 2012
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • Methods of treating heart failure using an anti-GM-CSF antibody
    Patent number: 8075885
    Abstract: This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: December 13, 2011
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • Antibodies to the PcrV antigen of
    Patent number: 8044181
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: October 25, 2011
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • EPHA3 ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA
    Publication number: 20110243934
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of multiple myeloma.
    Type: Application
    Filed: April 1, 2011
    Publication date: October 6, 2011
    Applicant: KaloBios Pharmaceuticals Inc.
    Inventors: Varghese Palath, Christopher R. Bebbington
  • GENERATION OF ANTIBODIES TO AN EPITOPE OF INTEREST
    Publication number: 20110245100
    Abstract: The invention provides methods of obtaining antibodies to an epitope of interest based on an anti-hapten focused library.
    Type: Application
    Filed: April 4, 2011
    Publication date: October 6, 2011
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Geoffrey T. Yarranton, Kenneth Luehrsen, Christopher R. Bebbington, Nenad Tomasevic
  • Antibody specificity transfer using minimal essential binding determinants
    Patent number: 7981843
    Abstract: The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.
    Type: Grant
    Filed: January 20, 2005
    Date of Patent: July 19, 2011
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Peter Flynn, Kenneth Luehrsen, Robert F. Balint, Jeng-Horng Her, Christopher R. Bebbington, Geoffrey T. Yarranton
  • METHOD OF TREATING A STAPHYLOCOCCUS INFECTION IN A PATIENT HAVING A LOW-LEVEL PATHOGENIC PSEUDOMONAS AERUGINOSA INFECTION
    Publication number: 20110165172
    Abstract: This invention provides methods of treating patients having a Staphylococcus infection where the patient also has a low level of Pseudomonas aeruginosa. The methods comprise administering an antagonist of the Pseudomonas Type III Secretion System, e.g., an anti-PcrV antibody antagonist.
    Type: Application
    Filed: December 21, 2010
    Publication date: July 7, 2011
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventor: Geoffrey T. Yarranton
  • Antibodies to EphA3
    Publication number: 20110123549
    Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: October 14, 2010
    Publication date: May 26, 2011
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
  • COMBINATION ANTIBIOTIC AND ANTIBODY THERAPY FOR THE TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION
    Publication number: 20100272736
    Abstract: The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with Pseudomonas aeruginosa infections, where the method comprises administering an antibiotic and an anti-PcrV antibody.
    Type: Application
    Filed: February 4, 2010
    Publication date: October 28, 2010
    Applicants: KaloBios Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Mark Baer, Christopher R. Bebbington, Geoffrey T. Yarranton, Susan Lynch, Yuanlin Song
  • Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3
    Publication number: 20100226930
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 9, 2010
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • METHODS OF TREATING DEMENTIA USING A GM-CSF ANTAGONIST
    Publication number: 20100215650
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: February 11, 2010
    Publication date: August 26, 2010
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
    Publication number: 20090274706
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: April 28, 2009
    Publication date: November 5, 2009
    Applicant: Kalobios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
  • Neutralization of GM-CSF for the Treatment of Heart Failure
    Publication number: 20090263387
    Abstract: This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist.
    Type: Application
    Filed: April 7, 2009
    Publication date: October 22, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • Antibodies to the PcrV Antigen of Pseudomonas aeruginosa
    Publication number: 20090191186
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: December 1, 2008
    Publication date: July 30, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • Methods of Treating Bone-Loss Disorders Using a GM-CSF Antagonist
    Publication number: 20090181020
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of bone loss disorders, such as osteopenia. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has a bone loss disorder and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: January 15, 2009
    Publication date: July 16, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. BEBBINGTON, Geoffrey T. Yarranton
  • EphA3 Antibodies for the Treatment of Solid Tumors
    Publication number: 20080286272
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.
    Type: Application
    Filed: March 10, 2008
    Publication date: November 20, 2008
    Applicants: KaloBios Pharmaceuticals, Inc., Ludwig Institute for Cancer Research, Monash University
    Inventors: Martin Lackmann, Andrew Mark Scott, Christopher R. Bebbington, Geoffrey T. Yarranton, Carmelina Murone, Catherine To
  • Methods for affinity maturation
    Patent number: 7432063
    Abstract: This invention provides methods of obtaining a binding molecule, e.g., an antibody, that has enhanced affinity for a binding partner relative to a reference binding molecule.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: October 7, 2008
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Robert F. Balint, Jeng-Horng Her
  • Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
    Publication number: 20080206241
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of chronic inflammatory disease, such as rheumatoid arthritis. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate, to a patient that has RA and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: November 21, 2007
    Publication date: August 28, 2008
    Applicant: KaloBios Pharmaceuticals Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • METHODS OF TREATING IDIOPATHIC THROMBOCYTOPENIA PURPURA USING A GM-CSF ANTAGONIST
    Publication number: 20080171038
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of Idiopathic Thrombocytopenia Purpura (ITP). Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has ITP and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: November 8, 2007
    Publication date: July 17, 2008
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton